Cellectis Reports Strong Phase 1 Data for Lasme-cel (100% ORR) and Promising Eti-cel Results at EHA
CLLS has more than doubled off its 52-week low of $1.327.
Summary
Cellectis presented highly encouraging final Phase 1 data for its lead CAR-T therapy, lasme-cel, showing a 100% overall response rate in a difficult-to-treat leukemia population, alongside promising preliminary data for eti-cel in lymphoma.
Key Events · Product Development and Regulatory · CLLS
-
Lasme-cel (BALLI-01) Final Phase 1 Data
Achieved a 100% overall response rate (ORR) and 57% complete remission/complete remission with incomplete count recovery (CR/CRi) in the target Phase 2 population of heavily pre-treated relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) patients.
-
Manageable Safety Profile
Lasme-cel demonstrated a manageable safety profile with low rates of severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
-
Eti-cel (NATHALI-01) Preliminary Data
Showed an 88% ORR and 63% complete response (CR) in the optimal dose cohort for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) patients, many of whom had prior CAR-T therapy.
-
Treatment Optimization Insights
Identified a positive correlation between alemtuzumab exposure and clinical outcomes for eti-cel, providing a rationale for optimizing lymphodepletion and enhancing CAR-T expansion.
Analysis · CLLS · Life Sciences
This filing provides strong clinical validation for Cellectis's allogeneic CAR-T pipeline. The 100% overall response rate for lasme-cel in heavily pre-treated B-ALL patients, coupled with a manageable safety profile, is a significant positive signal, especially following its recent FDA RMAT designation. The promising preliminary data for eti-cel in r/r B-NHL, including insights into optimizing treatment, further strengthens the company's therapeutic approach. These results are critical for advancing both programs into later-stage clinical trials and could significantly impact the company's valuation and future prospects.
At the time of this filing, CLLS was trading at $3.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.1M. The 52-week trading range was $1.33 to $5.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.